Test-retest reproducibility of radiomic features on PSMA-targeted F-18-DCFPyL PET/CT in patients with metastatic prostate cancer [Abstract]
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: Journal of Nuclear Medicine, 62, Suppl. 1, S. 1353-
- Event
-
Veröffentlichung
- (where)
-
Augsburg
- (who)
-
Universität Augsburg
- (when)
-
2021
- Event
-
Veröffentlichung
- (where)
-
New York, NY
- (who)
-
Society of Nuclear Medicine
- (when)
-
2021
- Creator
-
Wolf, Herta
Habacha, Bilel
Bundschuh, Lena
Higuchi, Takahiro
Serfling, Sebastian
Derlin, Thorsten
Essler, Markus
Lapa, Constantin Frederik Victor
Pienta, Kenneth
Buck, Andreas
Eisenberger, Mario
Markowski, Mark
Lodge, Martin
Pomper, Martin
Gorin, Michael
Rowe, Steven
Bundschuh, Ralph
- URN
-
urn:nbn:de:bvb:384-opus4-918498
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:55 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wolf, Herta
- Habacha, Bilel
- Bundschuh, Lena
- Higuchi, Takahiro
- Serfling, Sebastian
- Derlin, Thorsten
- Essler, Markus
- Lapa, Constantin Frederik Victor
- Pienta, Kenneth
- Buck, Andreas
- Eisenberger, Mario
- Markowski, Mark
- Lodge, Martin
- Pomper, Martin
- Gorin, Michael
- Rowe, Steven
- Bundschuh, Ralph
- Universität Augsburg
- Society of Nuclear Medicine
Time of origin
- 2021
Other Objects (12)
Test–retest repeatability of organ uptake on PSMA-targeted 18F-DCFPyL PET/CT in patients with prostate cancer
Test-retest repeatability of organ uptake on PSMA‐targeted 18F‐DCFPyL PET/CT in patients with prostate cancer
False-negative 18F-PSMA-1007 PET/CT in metastatic prostate cancer related to high physiologic liver uptake
Comparison of tumor heterogeneity assessed with textural parameters in 68Ga-PSMA PET/CT and 177Lu-PSMA SPECT/CT in patienst with metastatic prostate cancer
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
⁶⁸Ga-PSMA PET for the assessment of metastatic prostate cancer
PSMA-Liganden PET/CT bei Patienten mit biochemischem Rezidiv nach radikaler Prostatektomie: Matched-Pair Vergleich von 68Ga-PSMA-11 und 18F-PSMA-1007
Data on the test-retest reproducibility of streamline counts as a measure of structural connectivity
68Ga-PSMA I&T PET/CT for primary staging of prostate cancer
The PSMA-11-derived hybrid molecule PSMA-914 specifically identifies prostate cancer by preoperative PET/CT and intraoperative fluorescence imaging
68Ga-PSMA I&T PET/CT for primary staging of prostate cancer [Abstract]
Test–retest repeatability of organ uptake on PSMA-targeted 18F-DCFPyL PET/CT in patients with prostate cancer
Test-retest repeatability of organ uptake on PSMA‐targeted 18F‐DCFPyL PET/CT in patients with prostate cancer
False-negative 18F-PSMA-1007 PET/CT in metastatic prostate cancer related to high physiologic liver uptake
Comparison of tumor heterogeneity assessed with textural parameters in 68Ga-PSMA PET/CT and 177Lu-PSMA SPECT/CT in patienst with metastatic prostate cancer
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
⁶⁸Ga-PSMA PET for the assessment of metastatic prostate cancer
PSMA-Liganden PET/CT bei Patienten mit biochemischem Rezidiv nach radikaler Prostatektomie: Matched-Pair Vergleich von 68Ga-PSMA-11 und 18F-PSMA-1007
Data on the test-retest reproducibility of streamline counts as a measure of structural connectivity
68Ga-PSMA I&T PET/CT for primary staging of prostate cancer
The PSMA-11-derived hybrid molecule PSMA-914 specifically identifies prostate cancer by preoperative PET/CT and intraoperative fluorescence imaging
68Ga-PSMA I&T PET/CT for primary staging of prostate cancer [Abstract]
Test–retest repeatability of organ uptake on PSMA-targeted 18F-DCFPyL PET/CT in patients with prostate cancer
Test-retest repeatability of organ uptake on PSMA‐targeted 18F‐DCFPyL PET/CT in patients with prostate cancer
False-negative 18F-PSMA-1007 PET/CT in metastatic prostate cancer related to high physiologic liver uptake
Comparison of tumor heterogeneity assessed with textural parameters in 68Ga-PSMA PET/CT and 177Lu-PSMA SPECT/CT in patienst with metastatic prostate cancer
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
⁶⁸Ga-PSMA PET for the assessment of metastatic prostate cancer
PSMA-Liganden PET/CT bei Patienten mit biochemischem Rezidiv nach radikaler Prostatektomie: Matched-Pair Vergleich von 68Ga-PSMA-11 und 18F-PSMA-1007
Data on the test-retest reproducibility of streamline counts as a measure of structural connectivity
68Ga-PSMA I&T PET/CT for primary staging of prostate cancer
The PSMA-11-derived hybrid molecule PSMA-914 specifically identifies prostate cancer by preoperative PET/CT and intraoperative fluorescence imaging